Molecular signatures of soy-derived phytochemicals in androgen-responsive prostate cancer cells: A comparison study using DNA microarray

Molecular Carcinogenesis

Volumn 45, Issue 12, 2006, Pages 943-956

  Takahashi, Yoko ^a,b   Lavigne, Jackie A ^c   Hursting, Stephen D ^c   Chandramouli, Gadisetti V R ^c   Perkins, Susan N ^c   Kim, Young S ^c   Wang, Thomas T Y ^a  

^a BELTSVILLE HUMAN NUTRITION RESEARCH CENTER   (United States)

^b NATIONAL FOOD RESEARCH INSTITUTE   (Japan)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Equol; Isoflavone; Microarray; Prevention; Prostate cancer

Indexed keywords

ANDROGEN; DAIDZEIN; EQUOL; GENISTEIN; ISOFLAVONE; MITOGEN ACTIVATED PROTEIN KINASE; PLANT MEDICINAL PRODUCT; SOMATOMEDIN C;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GENETICS; CANCER RESEARCH; CELL ACTIVITY; CELL CYCLE; CELL STRAIN LNCAP; COMPARATIVE STUDY; CONTROLLED STUDY; DNA DETERMINATION; DNA MICROARRAY; GENE CONTROL; GENE EXPRESSION PROFILING; HORMONE RESPONSE; HUMAN; HUMAN CELL; MALE; MOLECULAR MECHANICS; MULTIDIMENSIONAL SCALING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; SOYBEAN; UNINDEXED SEQUENCE;

ANDROGENS; CELL CYCLE; CELL LINE, TUMOR; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENISTEIN; HUMANS; INSULIN-LIKE GROWTH FACTOR I; ISOFLAVONES; MALE; NEOPLASMS, HORMONE-DEPENDENT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHYTOESTROGENS; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; SOYBEANS;

EID: 33845403873     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20247     Document Type: Article

References (56)

1. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003;95:1276-1299.
2. Shirai T, Asamoto M, Takahashi S, Imaida K. Diet and prostate cancer. Toxicology 2002;181-182:89-94.
3. Greenwald P, Clifford CK, Milner JA. Diet and cancer prevention. Eur J Cancer 2001;37:948-965.
4. Greenwald P. Clinical trials of breast and prostate cancer prevention. J Nutr 2001;131:176S-178S.
5. Shibata A, Whittemore AS, Imai K, et al. Serum levels of prostate-specific antigen among Japanese-American and native Japanese men. J Natl Cancer Inst 1997;89:1716-1720.
6. Ziegler RG, Hoover RN, Pike MC, et al. Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst 1993;85:1819-1827.
7. Messina MJ. Emerging evidence on the role of soy in reducing prostate cancer risk. Nutr Rev, 2003;61:117-131.
8. Lamartiniere CA, Cotroneo MS, Fritz WA, Wang J, Mentor-Marcel R, Elgavish A. Genistein chemoprevention: Timing and mechanisms of action in murine mammary and prostate. J Nutr 2002;132:552S-558S.
9. Sarkar FH, Li Y. Mechanisms of cancer chemoprevention by soy isoflavone genistein. Cancer Metastasis Rev 2002;21:265-280.
10. Po LS, Wang TT, Chen ZY, Leung LK. Genistein-induced apoptosis in MCF-7 cells involves changes in Bak and Bcl-x without evidence of anti-oestrogenic effects. Br J Nutr 2002;88:463-469.
11. Leung LK, Wang TT. Bcl-2 is not reduced in the death of MCF-7 cells at low genistein concentration. J Nutr 2000;130:2922-2926.
12. Shen JC, Klein RD, Wei Q, et al. Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells. Mol Carcinog 2000;29:92-102.
13. Sathyamoorthy N, Gilsdorf JS, Wang TT. Differential effect of genistein on transforming growth factor beta 1 expression in normal and malignant mammary epithelial cells. Anticancer Res 1998;18:2449-2453.
14. Hong SJ, Kim SI, Kwon SM, Lee JR, Chung BC. Comparative study of concentration of isoflavones and lignans in plasma and prostatic tissues of normal control and benign prostatic hyperplasia. Yonsei Med J 2002;43:236-241.
15. King RA, Bursill DB. Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans. Am J Clin Nutr 1998;67:867-872.
16. Morton MS, Chan PS, Cheng C, et al. Lignans and isoflavonoids in plasma and prostatic fluid in men: Samples from Portugal, Hong Kong, and the United Kingdom. Prostate 1997;32:122-128.
17. Izumi T, Piskula MK, Osawa S, et al. Soy isoflavone aglycones are absorbed faster and in higher amounts than their glucosides in humans. J Nutr 2000;130:1695-1699.
18. Strom SS, Yamamura Y, Duphorne CM, et al. Phytoestrogen intake and prostate cancer: A case-control study using a new database. Nutr Cancer 1999;33:20-25.
19. Akaza H, Miyanaga N, Takashima N, et al. Is daidzein non-metabolizer a high risk for prostate cancer? A case-controlled study of serum soybean isoflavone concentration. Jpn J Clin Oncol 2002;32:296-300.
20. Ozasa K, Nakao M, Watanabe Y, et al. Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men. Cancer Sci 2004;95:65-71.
21. Sathyamoorthy N, Wang TT. Differential effects of dietary phyto-oestrogens daidzein and equol on human breast cancer MCF-7 cells. Eur J Cancer 1997;33:2384-2389.
22. Lund TD, Munson DJ, Haldy ME, Setchell KD, Lephart ED, Handa RJ. Equol is a novel anti-androgen that inhibits prostate growth and hormone feedback. Biol Reprod 2004;70:1188-1195.
23. Hedlund TE, Johannes WU, Miller GJ. Soy isoflavonoid equol modulates the growth of benign and malignant prostatic epithelial cells in vitro. Prostate 2003;54:68-78.
24. Hedlund TE, Maroni PD, Ferucci PG, et al. Long-term dietary habits affect soy isoflavone metabolism and accumulation in prostatic fluid in Caucasian men. J Nutr 2005;135:1400-1406.
25. Takahashi Y, Lavigne JA, Hursting SD, et al. Using DNA microarray analyses to elucidate the effects of genistein in androgen-responsive prostate cancer cells: Identification of novel targets. Mol Carcinog 2004;41:108-119.
26. Li Y, Sarkar FH. Gene expression profiles of genistein-treated PC3 prostate cancer cells. J Nutr 2002;132:3623-3631.
27. Cox TF, Cox MAA. Multidimensional scaling. London: Chapman & Hall, 1994; 213p.
28. Hosack DA, Dennis G Jr, Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol 2003;4:R70.
29. Eisen MB, Spellman PT, Brown PO, Botstein D, Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863-14868.
30. Alon U, Barkai N, Notterman DA, et al. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci USA 1999;96:6745-6750.
31. Nelson PS, Clegg N, Arnold H, et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci USA 2002;99:11890-11895.
32. Pons S, Asano T, Glasheen E, et al. The structure and function of p55PIK reveal a new regulatory subunit for phosphatidylinositol 3-kinase. Mol Cell Biol 1995;15:4453-4465.
33. Dixon SC, Knopf KB, Figg WD. The control of prostate-specific antigen expression and gene regulation by pharmacological agents. Pharmacol Rev 2001;53:73-91.
34. Johnston AM, Naselli G, Gonez LJ, Martin RM, Harrison LC, DeAizpurua HJ. SPAK, a STE20/SPS1-related kinase that activates the p38 pathway. Oncogene 2000;19:4290-4297.
35. Korkmaz KS, Korkmaz CG, Ragnhildstveit E, Kizildag S, Pretlow TG, Saatcioglu F. Full-length cDNA sequence and genomic organization of human NKX3A-alternative forms and regulation by both androgens and estrogens. Gene 2000;260:25-36.
36. Spicer AP, Kaback LA, Smith TJ, Seldin MF. Molecular cloning and characterization of the human and mouse UDP-glucose dehydrogenase genes. J Biol Chem 1998;273:25117-25124.
37. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000;183:1-9.
38. Reynolds RA, Yem AW, Wolfe CL, Deibel MR Jr, Chidester CG, Watenpaugh KD. Crystal structure of the catalytic subunit of Cdc25B required for G2/M phase transition of the cell cycle. J Mol Biol 1999;293:559-568.
39. Turowski P, Franckhauser C, Morris MC, Vaglio P, Fernandez A, Lamb NJ. Functional cdc25C dual-specificity phosphatase is required for S-phase entry in human cells. Mol Biol Cell 2003;14:2984-2998.
40. Henglein B, Chenivesse X, Wang J, Eick D, Brechot C. Structure and cell cycle-regulated transcription of the human cyclin A gene. Proc Natl Acad Sci USA 1994;91:5490-5494.
41. Sarafan-Vasseur N, Lamy A, Bourguignon J. Overexpression of B-type cyclins alters chromosomal segregation. Oncogene 2002;21:2051-2057.
42. el-Deiry WS, Tokino T, Velculescu VE. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825.
43. Yin MB, Hapke G, Wu J, et al. Chk1 signaling pathways that mediated G(2)M checkpoint in relation to the cellular resistance to the novel topoisomerase I poison BNP1350. Biochem Biophys Res Commun 2002;295:435-444.
44. Kumagai H, Sato N, Yamada M, et al. A novel growth- and cell cycle-regulated protein, ASK, activates human Cdc7-related kinase and is essential for G1/S transition in mammalian cells. Mol Cell Biol 1999;19:5083-5095.
45. Zerbe LK, Kuchta RD. The p58 subunit of human DNA primase is important for primer initiation, elongation, and counting. Biochemistry 2002;41:4891-4900.
46. Ishimi Y, Komamura-Kohno Y, Kwon HJ, Yamada K, Nakanishi M. Identification of MCM4 as a target of the DNA replication block checkpoint system. J Biol Chem 2003;278:24644-24650.
47. Shohet JM, Hicks MJ, Plon SE, et al. Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma. Cancer Res 2002;62:1123-1128.
48. Loeber G, Dworkin MB, Infante A, Ahorn H. Characterization of cytosolic malic enzyme in human tumor cells. FEBS Lett 1994;344:181-186.
49. Guillemette C, Levesque E, Beaulieu M, Turgeon D, Hum DW, Belanger A. Differential regulation of two uridine diphospho-glucuronosyltransferases, UGT2B15 and UGT2B17, in human prostate LNCaP cells. Endocrinology. 1997;138:2998-3005.
50. Brondello JM, Brunet A, Pouyssegur J, McKenzie FR. The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44MAPK cascade. J Biol Chem 1997;272:1368-1376.
51. Hennessy SW, Frazier BA, Kim DD, et al. Complete thrombospondin mRNA sequence includes potential regulatory sites in the 3′ untranslated region. J Cell Biol 1989;108:729-736.
52. Ye R, Goodarzi AA, Kurz EU, et al. The isoflavonoids genistein and quercetin activate different stress signaling pathways as shown by analysis of site-specific phosphorylation of ATM, p53 and histone H2AX. DNA Repair 2004;3:235-244.
53. Debes JD, Tindall DJ. The role of androgens and the androgen receptor in prostate cancer. Cancer Lett 2002;187:1-7.
54. Hedlund TE, van Bokhoven A, Johannes WU, Nordeen SK, Ogden LG. Prostatic fluid concentrations of isoflavonoids in soy consumers are sufficient to inhibit growth of benign and malignant prostatic epithelial cells in vitro. Prostate 2006;66:557-566.
55. Onozawa M, Fukuda K, Ohtani M, Akaza H, Sugimura T, Wakabayashi K. Effects of soybean isoflavones on cell growth and apoptosis of the human prostatic cancer cell line LNCaP. Jpn J Clin Oncol 1998;28:360-363.
56. Zhou JR, Gugger ET, Tanaka T, Guo Y, Blackburn GL, Clinton SK. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr 1999;129:1628-1 635.